ADVENTRX Announces Completion Of Patient Enrollment In ANX-530 Marketing-Enabling Clinical Study
Oct 11th 2007Drug InformationClinical Trials
ADVENTRX Pharmaceuticals, Inc. (Amex: ANX), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases, announced that it has completed patient enrollment in its marketing-enabling clinical study of ANX-530 (vinorelbine emulsion), a novel, emulsion formulation of vinorelbine tartrate. [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
